Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of dolutegravir with either tenofovir disoproxil fumarate/emtricitabine or tenofovir disoproxil fumarate/lamivudine compared to those switched to SOC boosted-PI ART (lopinavir/ritonavir or atazanavir/r, zidovudine, lamivudine)

Next Previous
Trial Profile

Efficacy of dolutegravir with either tenofovir disoproxil fumarate/emtricitabine or tenofovir disoproxil fumarate/lamivudine compared to those switched to SOC boosted-PI ART (lopinavir/ritonavir or atazanavir/r, zidovudine, lamivudine)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Emtricitabine (Primary) ; Lamivudine (Primary) ; Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Atazanavir/ritonavir; Lopinavir/ritonavir; Zidovudine
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms VISEND

Most Recent Events

  • 06 Mar 2024 Results evaluating the safety and efficacy of second-line treatment, after NNRTI failure, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
  • 22 Feb 2023 Results (n=783) assessing the effect baseline drug resistant mutations to NRTI on virologic outcome in patients switched from tenofovir disoproxil fumarate, Lamivudine, Efavirenz or Nevirapine to Dolutegravir combined with either TDF,3TC [TLD] or TAF,FTC [TAFED], or ZDV, 3TC with a boosted protease inhibitor of either lopinavir/ritonavir or atazanavir/ritonavir in the VISEND trial, presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023.
  • 26 Oct 2022 Results from DolPHIN-2, ADVANCE, NAMSAL and VISEND, comparing rates of virological failure (VF)and re-suppression in four randomised trials of dolutegravir (DTG), efavirenz (EFV) and protease inhibitors , presented at the 16th International Congress on Drug Therapy and HIV Infection

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top